Scott N Boyle is Chief Business Officer of C4 Therapeutics, Inc.. Currently has a direct ownership of 52,330 shares of CCCC, which is worth approximately $305,083. The most recent transaction as insider was on Feb 14, 2024, when has been sold 27,300 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 52.3K
0% 3M change
95.52% 12M change
Total Value Held $305,083

Scott N Boyle Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 14 2024
BUY
Grant, award, or other acquisition
-
27,300 Added 34.28%
52,330 Common Stock
Feb 13 2024
SELL
Payment of exercise price or tax liability
$11,329 $6.53 p/Share
1,735 Reduced 6.48%
25,030 Common Stock
Aug 30 2023
SELL
Payment of exercise price or tax liability
$1,936 $2.93 p/Share
661 Reduced 2.41%
26,765 Common Stock
Aug 30 2023
BUY
Exercise of conversion of derivative security
-
2,250 Added 7.58%
27,426 Common Stock
Feb 13 2023
BUY
Grant, award, or other acquisition
-
20,000 Added 44.27%
25,176 Common Stock
Jan 30 2023
SELL
Payment of exercise price or tax liability
$9,507 $7.78 p/Share
1,222 Reduced 19.1%
5,176 Common Stock
Jan 30 2023
BUY
Exercise of conversion of derivative security
-
3,750 Added 36.95%
6,398 Common Stock
May 25 2022
BUY
Exercise of conversion of derivative security
-
3,750 Added 50.0%
3,750 Common Stock
SNB

Scott N Boyle

Chief Business Officer
Watertown, MA

Track Institutional and Insider Activities on CCCC

Follow C4 Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CCCC shares.

Notify only if

Insider Trading

Get notified when an C4 Therapeutics, Inc. insider buys or sells CCCC shares.

Notify only if

News

Receive news related to C4 Therapeutics, Inc.

Track Activities on CCCC